Latest news with #Immunization
CNN
02-08-2025
- Health
- CNN
HHS further constrains certain vaccine advisers to the CDC, limiting their input in evidence reviews
Vaccines Federal agenciesFacebookTweetLink Follow In a further jolt to the process of reviewing and recommending vaccines at the US Centers for Disease Control and Prevention, another group of outside advisers to the agency was abruptly sidelined this week. In an email sent late Thursday evening, which was obtained by CNN, members of roughly 30 medical and public health organizations who serve as liaison members of the CDC's Advisory Committee on Immunization Practices, or ACIP, were told they could no longer participate in the committee's crucial workgroups. Liaison members don't vote at ACIP's public meetings on vaccine recommendations, but they can participate by asking questions and commenting on presentations. Behind the scenes, they have also historically done important work undertaking detailed evidence reviews of the safety and effectiveness of vaccines that helps to inform the group's votes. Those reviews happen in subcommittees called workgroups. As of late last year, ACIP had 11 active workgroups. In addition to studying scientific research, workgroups consider issues of public health importance like what age groups might get the most benefit from a vaccine, what an immunization costs and whether it will be accessible to people who should get it. Workgroups also help craft the language of the recommendations that are voted on by the full committee. Votes are typically held during ACIP's three public meetings each year. If ACIP approves a recommendation, it's forwarded to the CDC director for consideration. The director isn't bound by the committee's recommendation but usually follows it. Liaisons include groups like the American Medical Association, the American Academy of Pediatrics and the American Pharmacists Association. Members also represent nurses and public health officials, typically groups that play a significant role in delivering vaccinations. The latest move comes more than a month after US Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 voting members of ACIP, replacing them days later with eight of his own picks, many of whom have cast doubt on the safety of vaccines and public policy around vaccination. One member later dropped out during the required financial review. The email sent Thursday called the liaison members 'special interest groups' that are 'expected to have a 'bias' based on their constituency and/or population they represent.' 'It is important that the ACIP workgroup activities remain free of any influence from any special interest groups so ACIP workgroups will no longer include Liaison organizations,' the email said. Andrew Nixon, director of communications for HHS, said in a statement Friday that 'Under the old ACIP, outside pressure to align with vaccine orthodoxy limited asking the hard questions. The old ACIP members were plagued by conflicts of interest, influence and bias. We are fulfilling our promise to the American people to never again allow those conflicts to taint vaccine recommendations.' Dr. William Schaffner, an infectious disease expert at Vanderbilt University who has been participating in ACIP for 40 years as both a voting member and a liaison member, said the move to exclude professional organizations from the process of making vaccine recommendations was shortsighted. 'The organizations have a certain ownership in the recommendations because they participate,' Schaffner said. That participation increases buy-in from different stakeholder groups, which helps ACIP recommendations become the accepted standards of medical practice. Without that participation, Schaffner said, there's a risk that groups will make their own vaccine recommendations, which could lead to conflicting and confusing advice. In fact, some outside organizations, including the Vaccine Integrity Project, have already started the process of making independent vaccination recommendations. Shaffner said he also takes issue with the idea that liaison representatives are biased, which he says implies a conflict of interest. 'Every work group member, no matter who they are, is vetted for a conflict of interest,' he said, and that vetting process has only become more stringent over time as society has become more attuned to the problem. 'I have to turn down opportunities because they would interfere with my being on a work group, and that's something I do, or did,' he said. ACIP's charter spells out that some 30 specific groups should hold non-voting seats on the committee. It also allows the HHS secretary to appoint other liaison members as necessary to carry out the functions of the committee. On Friday, eight organizations that are liaisons to the committee said in a joint statement that they were 'deeply disappointed' and 'alarmed' to be barred from reviewing scientific data and informing the development of vaccine recommendations. 'To remove our deep medical expertise from this vital and once transparent process is irresponsible, dangerous to our nation's health, and will further undermine public and clinician trust in vaccines,' said the statement, which was sent by the American Medical Association. New outside experts may be invited to participate in the workgroups as needed based on their expertise, according to an HHS official who spoke on the condition that they not be named because they had not been authorized to share the information, but such inclusion will no longer be based on organizational affiliation. 'Many of these groups don't like us,' the official said. 'They've publicly attacked us.'
Daily Mail
20-05-2025
- Health
- Daily Mail
Trump's FDA announces radical change to Covid vaccine schedule that will affect millions
The FDA has revealed a radical shift in its Covid vaccination policy. The agency says it is now set to only recommend Covid vaccines to older adults over 65 and people who are immunocompromised. It marks a major shift from the current policy, recommending a dose of the updated Covid vaccine to everyone aged six months and over. And it could leave millions unable to get the vaccine through their health insurance. But the FDA head Dr Marty Makary says the change is needed, adding that there is no clear benefit from vaccinating millions of healthy people against Covid every year. He says it has fostered public distrust and led many to forgo vital vaccinations, such as that against measles — with the US recording its biggest outbreak in two decades this year. The new policy was revealed in an editorial published Tuesday in the New England Journal of Medicine, authored by Dr Makary and the FDA's head on vaccines Dr Vinay Prasad. It is set to be unveiled at a press conference later today, and will likely affect people seeking an updated Covid shot in fall 2025. They wrote: 'Over the past two seasons, uptake of the annual Covid booster has been poor. Less than 25 percent of Americans received boosters each year. 'There may even be a ripple effect: Public trust in vaccination in general has declined, resulting in a reluctance to vaccinate that is affecting even vital immunization programs such as that for measles-mumps-rubella vaccination.' The change will more closely align the US with other nations, like the UK, Canada and Australia — which all only recommend updated Covid shots to older adults. Uptake of the updated Covid vaccinations has been in free-fall, with latest CDC data showing barely 20 percent of adults received the shot this respiratory virus season. The pair added: 'While all other high-income nations confine vaccine recommendations to older adults (typically those older than 65 years of age), or those at high risk for severe Covid... '... the US adopted a one-size-fits-all regulatory framework and has granted broad marketing authoritzation to all Americans over the age of six months.' 'The US policy has sometimes been justified by arguing that the American people are not sophisticated enough to understand age- and risk-based recommendations. 'We reject this view.' The pair said Covid vaccines for young adults would be approved, but only after pharmaceutical companies could demonstrate that they create protective antibody concentrations in the group. Dr Noel Brewer, a public health expert at the University of North Carolina, Chapel Hill, and who sits on the CDC's vaccine recommendation committee, told CNN that he supported the change. 'The proposed policy moves the US into line with other countries. This global view of public health is a welcome development,' he said. Dr Paul Offit, a pediatrician at the Children's Hospital of Philadelphia and a member of the FDA's vaccines advisory group, disagreed, however. He said: 'We have been using an evidence-based approach to Covid vaccination, but they kind of swoop in and believe that for the first time, we're going to get, as they say, "gold standard" data, robust data, for the first time, because, according to them, we don't have that, but we do have that. 'That's why we've made good decisions about the vaccines. That's why that vaccine is remarkably safe. I mean, the mRNA vaccines are remarkably safe.' The FDA is set to announce the policy in a press conference at 1pm today.
Bloomberg
19-05-2025
- Health
- Bloomberg
FDA to Unveil Covid Vaccine Policy as RFK Jr. Eyes Placebo Tests
President Donald Trump's administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could spell major changes in what is required to get regulatory approval for immunizations. The US Food and Drug Administration 's YouTube channel is featuring an upcoming town hall, set to begin Tuesday at 1 p.m. in Washington, titled 'An evidence based approach to Covid vaccination.' The two speakers listed are FDA Commissioner Marty Makary and Vinay Prasad, an outspoken critic of the drug industry who was recently appointed to lead the agency's division that oversees vaccines.
Yahoo
16-05-2025
- Health
- Yahoo
Adult Vaccine Market Forecast Report 2025-2033: Increasing Geriatric Population and Immunosenescence, Increasing Government Vaccination Campaigns and Awareness, Advancements in Innovations
Adult Vaccine Market Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Global Adult Vaccines Market was worth USD 21.77 billion in 2024 and is forecasted to hit USD 37.18 billion by the end of 2033 at a CAGR of 6.13% between 2025 and 2033. Demand for vaccines increases due to mounting awareness regarding immunization in adults, high disease incidence, and an ageing global population. Adult vaccines are the vaccines specifically for persons 18 years and above that are given to prevent disease from various infections. Although vaccination in childhood establishes initial immunity, adult immunization is important to sustain long-term health and ward off disease epidemics. Vaccines commonly recommended for adults are against influenza, hepatitis A and B, human papillomavirus (HPV), herpes zoster or shingles, pneumococcal disease, tetanus, and diphtheria. These vaccines are especially crucial for older adults, those with chronic diseases, healthcare personnel, and travelers. The demand for adult vaccines has increased across the world, particularly after the COVID-19 pandemic, which showed the importance of immunization among elderly people. Governments and health bodies increasingly advocate for adult immunization through increased awareness campaigns and standard health check-ups. Industrialized countries like Europe and North America have established adult vaccination programs, whereas developing economies in Asia-Pacific, Latin America, and the Middle East are building their public health infrastructure to enhance adult vaccine coverage. This change is generating robust global demand for adult Drivers in the Global Adult Vaccines Market Increasing Geriatric Population and ImmunosenescenceThe world population is growing old very fast, thus increasing the age-related diseases and a compromised immune system, which is referred to as immunosenescence. As people grow older, they become weaker in fighting infections, and immunization at the right time becomes necessary. Vaccines like influenza, shingles, and pneumococcal are most sought after among the elderly. By 2030, 1 in 6 individuals on the planet will be 60 years or older, with this age group growing from 1 billion in 2020 to 1.4 billion. By 2050, it will reach 2.1 billion, and those 80 and above will triple to 426 million. As a result, global healthcare systems are adding routine adult immunization to preventive care plans. This demographic shift is strongly propelling the demand for adult vaccines and motivating pharmaceutical firms to develop age-specific and more potent Government Vaccination Campaigns and AwarenessGovernments and global health agencies are stepping up efforts to promote adult immunization through awareness campaigns and subsidized vaccination programs. Programs like the CDC's adult immunization schedule and WHO's expanded immunization agenda are raising public awareness and acceptance of adult vaccines. These initiatives focus on preventing preventable hospitalizations, minimizing healthcare expenditures, and restraining the spread of preventable disease among adults. With supportive regulatory measures and increased public health focus, these initiatives are driving up higher vaccine penetration rates in developed and emerging economies, serving as a key market growth catalyst. World Immunization Week, which occurs during the fourth week of April 2025, encourages the value of immunization to safeguard all ages against vaccine-preventable diseases. The Vaccines National Strategic Plan 2021-2025 provides the U.S. vision for the elimination of these diseases within the next five in Vaccine Technology and InnovationInnovations in vaccine technology - recombinant DNA methods, mRNA platforms, and adjuvant systems - are improving vaccine efficacy, safety, and shelf life. These advances facilitate quicker production of adult-specific needs vaccines such as HPV, shingles, and flu. Further, the COVID-19 pandemic catapulted R&D spending and collaborations, which overtrickled into wider vaccine innovation. Pharmaceutical companies are currently concentrating on combination vaccines and multivalent adult vaccines with enhanced convenience and coverage. These technological leaps are opening up new opportunities in the global adult vaccines market, encouraging wider immunization across various adult age groups. April 2025, Uganda's Ministry of Health has confirmed the introduction of the R21/Matrix-MT malaria vaccine into routine immunization, making it the 19th African country to do so. The vaccine will first target 1.1 million children under the age of two in 105 high- and moderate-transmission districts, with nationwide rollout Adult Vaccines Market Challenges Vaccine Hesitancy and MisinformationDespite demonstrated efficacy, adult vaccination is resisted due to pervasive misinformation and doubt. Adult individuals downplay the danger of vaccine-preventable disease or feel immunization is solely needed during childhood. Social media sites frequently drive vaccine hesitancy by disseminating false information regarding side effects and safety. This resistance impedes uptake, particularly in low- and middle-income countries with poor health literacy. Addressing misinformation and enhancing trust in public health advice is critical to overcoming this obstacle and attaining widespread adult vaccine Costs and Restricted Access in Low-Income AreasAdult vaccines may be costly, especially in nations without universal healthcare coverage. In low-income areas, access to crucial vaccines is restricted because of poor infrastructure, lack of cold chain logistics, and prohibitive out-of-pocket expenses. In contrast to pediatric vaccines, that are subsidized or delivered through global schemes such as GAVI, adult immunization does not have a similar financing arrangement in most nations. Such an approach of financing and logistics hampers the distribution of vaccines as well as efforts to establish a robust adult immunization program, thus slowing market growth overall. Key Players Analysis: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue GlaxoSmithKline, plc. AstraZeneca plc Sanofi Pasteur Pfizer, Inc. CSL Limited Bristol-Myers Squibb Company Pfizer Inc. Novarts AG Johnson & Johnson Eli Lily Company Seattle Genetics Inc Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21.77 Billion Forecasted Market Value (USD) by 2033 $37.18 Billion Compound Annual Growth Rate 6.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Driver4.2 Challenges5. Global Adult Vaccines Market5.1 Market5.2 Volume (people)6. Adult Vaccines Market & Numbers Share Analysis6.1 Adult Vaccine Market Share6.2 By Country Adult Vaccine Market Share6.3 Adult Vaccinated Population Share7. Disease wise - Adult Vaccines Market7.1 Influenza7.2 Cervical Cancer (HPV)7.3 Zoster (Shingles)7.4 MMR (Measles, Mumps, and Rubella Vaccine)7.5 Pneumococcal7.6 Meningococcal7.7 Hepatitis7.8 TdaP7.9 Travel and Miscellaneous7.10 Varicella8. Disease wise - Numbers of Vaccinated Adults8.1 Influenza8.2 Cervical Cancer (HPV)8.3 Zoster (Shingles)8.4 MMR8.5 Pneumococcal8.6 Meningococcal8.7 Hepatitis8.8 TdaP8.9 Varicella9. Country9.1 North America9.1.1 United States9.1.2 Canada9.2 Europe9.2.1 United Kingdom9.2.2 Germany9.2.3 France9.2.4 Russia9.2.5 Italy9.2.6 Spain9.2.7 Switzerland9.3 Asia-Pacific9.3.1 India9.3.2 China9.3.3 Japan9.3.4 Australia9.3.5 South Korea9.4 Latin Africa9.4.1 Mexico9.4.2 Brazil9.4.3 Argentina9.5 Middle East and Africa9.5.1 Saudi Arabia9.5.2 UAE9.5.3 South Africa9.6 Rest of the World10. Porter's Five Forces10.1 Bargaining Power of Buyers10.2 Bargaining Power of Suppliers10.3 Degree of Competition10.4 Threat of New Entrants10.5 Threat of Substitutes11. SWOT Analysis11.1 Strengths11.2 Weaknesses11.3 Opportunities11.4 Threats12. Mergers and Acquisitions in the Vaccine Industry13. Vaccines and Regulator's Interventions13.1 Making and Meeting Standards of Quality and Safety13.2 Vaccine Funding14. Vaccines - Products and Pipeline14.1 GSK Vaccine Product Pipeline14.2 AstraZeneca plc Vaccine Product Pipeline14.3 Sanofi Vaccine Product Pipeline14.4 Pfizer Vaccine Product Pipeline15. Vaccines Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Adult Vaccine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
